Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 2Phase EARLY_PHASE1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Endocrine 2Gastrointestinal 1Breast 1

Conditions

Neuroendocrine Tumors 1Advanced Gastroenteropancreatic Neuroendocrine Tumor 1

Interventions

Everolimus 7lutetium Lu 177 dotatate 6lanreotide 5Octreotide 5177Lu-octreotide, DOTA(0)-Tyr(3)- 4amino-acid, glucose, and electrolyte solution 3Capecitabine 3surufatinib 2pasireotide 2fluorodopa F 18 2Temozolomide 2Lutetium-177 2Lutetium 2Introns 2Ga(III)-DOTATOC 2telotristat ethyl 1pembrolizumab 1copper dotatate CU-64 1cabozantinib 1X-Rays 1Watchful Waiting 1Sunitinib 1Specimen Handling 1Somatostatin 1Serotonin 1Salts 1Receptor-Like Protein Tyrosine Phosphatases, Class 2 1Phantoms, Imaging 1Oxaliplatin 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Ga(III)-DOTATOC × NET × Clear all
NCT06091748 2025-06-03

Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Recruiting
66 enrolled
EndocrineGastrointestinalNET

Advanced Gastroenteropancreatic Neuroendocrine Tumor

NCT03136328 2023-05-09

Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan

Montefiore Medical Center

Phase 3 Completed
11 enrolled 5 charts
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡